Recommended Topic Related To:

Synercid

"A family of bacteria has become increasingly resistant to last-resort antibiotics during the past decade, and more hospitalized patients are getting lethal infections that, in some cases, are impossible to cure. The findings, published today"...

Synercid

Synercid

SIDE EFFECTS

The safety of Synercid was evaluated in 1099 patients enrolled in 5 comparative clinical trials. Additionally, 4 non-comparative clinical trials (3 prospective and 1 retrospective in design) were conducted in which 1199 patients received Synercid for infections due to Gram-positive pathogens for which no other treatment option was available. In non-comparative trials, the patients were severely ill, often with multiple co-morbidities or physiological impairments, and may have been intolerant to or failed other antibacterial therapies.

Comparative Trials

Adverse Reaction Summary – All Comparative Studies

Safety data are available from five comparative clinical studies (n= 1099 Synercid; n= 1095 comparator). One of the deaths in the comparative studies was assessed as possibly related to Synercid. The most frequent reasons for discontinuation due to drug-related adverse reactions were as follows:

% of patients discontinuing therapy by reaction type

Type Synercid Comparator
Venous 9.2 2.0
Non-venous 9.6 4.3
-Rash 1.0 0.5
-Nausea 0.9 0.6
-Vomiting 0.5 0.5
-Pain 0.5 0.0
-Pruritus 0.5 0.3

Clinical Reactions – All Comparative Studies

Adverse reactions with an incidence of ≥ 1% and possibly or probably related to Synercid administration include:

Adverse Reactions % of patients with adverse reactions
Synercid Comparator
Inflammation at infusion site 42.0 25.0
Pain at infusion site 40.0 23.7
Edema at infusion site 17.3 9.5
Infusion site reaction 13.4 10.1
Nausea 4.6 7.2
Thrombophlebitis 2.4 0.3
Diarrhea 2.7 3.2
Vomiting 2.7 3.8
Rash 2.5 1.4
Headache 1.6 0.9
Pruritus 1.5 1.1
Pain 1.5 0.1

Additional adverse reactions that were possibly or probably related to Synercid with an incidence less than 1% within each body system are listed below:

Body as a Whole: abdominal pain, worsening of underlying illness, allergic reaction, chest pain, fever, infection;

Cardiovascular: palpitation, phlebitis;

Digestive: constipation, dyspepsia, oral moniliasis, pancreatitis, pseudomembranous enterocolitis, stomatitis;

Metabolic: gout, peripheral edema;

Musculoskeletal: arthralgia, myalgia, myasthenia;

Nervous: anxiety, confusion, dizziness, hypertonia, insomnia, leg cramps, paresthesia, vasodilation;

Respiratory: dyspnea, pleural effusion;

Skin and Appendages: maculopapular rash, sweating, urticaria;

Urogenital: hematuria, vaginitis

Clinical Reactions – Skin And Skin Structure Studies

In two of the five comparative clinical trials Synercid (n=450) and comparator regimens (e.g., oxacillin/vancomycin or cefazolin/vancomycin; n=443) were studied for safety and efficacy in the treatment of complicated skin and skin structure infections. The adverse event profile seen in the Synercid patients in these two studies differed significantly from that seen in the other comparative studies. What follows is safety data from these two studies.

Discontinuation of therapy was most frequently due to the following drug related events:

Type % of patients discontinuing therapy by reaction type
Synercid Comparator
Venous 12.0 2.0
Non-venous 11.8 4.0
-Rash 2.0 0.9
-Nausea 1.1 0.0
-Vomiting 0.9 0.0
-Pain 0.9 0.0
-Pruritus 0.9 0.5

Venous adverse events were seen predominately in patients who had peripheral infusions. The most frequently reported venous and non-venous adverse reactions possibly or probably related to study drug were:

  % of patients with adverse reactions
Synercid Comparator
Venous 68.0 32.7
-Pain at infusion site 44.7 17.8
-Inflammation at infusion site 38.2 14.7
-Edema at infusion site 18.0 7.2
-Infusion site reaction 11.6 3.6
Non-venous 24.7 13.1
-Nausea 4.0 2.0
-Vomiting 3.7 1.0
-Rash 3.1 1.3
-Pain 3.1 0.2

There were eight (1.7%) episodes of thrombus or thrombophlebitis in the Synercid arms and none in the comparator arms.

Laboratory Events-All Comparative Studies

The following table shows the number (%) of patients exhibiting laboratory values above or below the clinically relevant “critical” values during treatment phase (with an incidence of 0.1% or greater in either treatment group).

Parameter Critically High or Low Value Synercid Critically High or Low Comparator Critically High or Low
AST > 10 x ULN 9 (0.9) 2 (0.2)
ALT > 10 x ULN 4 (0.4) 4 (0.4)
Total Bilirubin > 5 x ULN 9 (0.9) 2 (0.2)
Conjugated Bilirubin > 5 x ULN 29 (3.1) 12 (1.3)
LDH > 5 x ULN 10 (2.6) 8 (2.1)
Alk Phosphatase > 5 x ULN 3 (0.3) 7 (0.7)
Gamma-GT > 10 x ULN 19 (1.9) 10 (1.0)
CPK > 10 x ULN 6 (1.6) 5 (1.4)
Creatinine ≥ 440 μmoL/L 1 (0.1) 1 (0.1)
BUN ≥ 35.5 mmoL/L 2 (0.3) 9 (1.2)
Blood Glucose > 22.2 mmoL/L 11 (1.3) 11 (1.3)
  < 2.2 mmoL/L 1 (0.1) 1 (0.1)
Bicarbonates > 40 mmoL/L 2 (0.3) 3 (0.5)
  < 10 mmoL/L 3 (0.5) 3 (0.5)
CO2 > 50 mmoL/L 0 (0.0) 0 (0.0)
  < 15 mmoL/L 1 (0.2) 0 (0.0)
Sodium > 160 mmoL/L 0 (0.0) 0 (0.0)
  < 120 mmoL/L 5 (0.5) 3 (0.3)
Potassium > 6.0 mmoL/L 3 (0.3) 6 (0.6)
  < 2.0 mmoL/L 0 (0.0) 1 (0.1)
Hemoglobin < 8 g/dL 25 (2.6) 16 (1.6)
Hematocrit > 60% 2 (0.2) 0 (0.0)
Platelets > 1,000,000/mm³ 2 (0.2) 2 (0.2)
  < 50,000/mm³ 6 (0.6) 7 (0.7)

 

Non-Comparative Trials

Clinical Adverse Reactions

Approximately one-third of patients discontinued therapy in these trials due to adverse events. However, the discontinuation rate due to adverse reactions assessed by the investigator as possibly or probably related to Synercid therapy was approximately 5.0%.

There were three prospectively designed non-comparative clinical trials in patients (n = 972) treated with Synercid. One of these studies (301), had more complete documentation than the other two (398A and 398B). The most common events probably or possibly related to therapy were:

Adverse Reactions % of patients with adverse reaction
Study 301 Study 398A Study 398B
Arthralgia 7.8 5.2 4.3
Myalgia 5.1 0.95 3.1
Arthralgia and Myalgia 7.4 3.3 6.8
Nausea 3.8 2.8 4.9

The percentage of patients who experienced severe related arthralgia and myalgia was 3.3% and 3.1%, respectively. The percentage of patients who discontinued treatment due to related arthralgia and myalgia was 2.3% and 1.8%, respectively.

Laboratory Events

The most frequently observed abnormalities in laboratory studies were in total and conjugated bilirubin, with increases greater than 5 times upper limit of normal, irrespective of relationship to Synercid, reported in 25.0% and 34.6% of patients, respectively. The percentage of patients who discontinued treatment due to increased total and conjugated bilirubin was 2.7% and 2.3%, respectively. Of note, 46.5% and 59.0% of patients had high baseline total and conjugated bilirubin levels before study entry.

Other

Serious adverse reactions in clinical trials, including non-comparative studies, considered possibly or probably related to Synercid administration with an incidence < 0.1% include: acidosis, anaphylactoid reaction, apnea, arrhythmia, bone pain, cerebral hemorrhage, cerebrovascular accident, coagulation disorder, convulsion, dysautonomia, encephalopathy, grand mal convulsion, hemolysis, hemolytic anemia, heart arrest, hepatitis, hypoglycemia, hyponatremia, hypoplastic anemia, hypoventilation, hypovolemia, hypoxia, jaundice, mesenteric arterial occlusion, neck rigidity, neuropathy, pancytopenia, paraplegia, pericardial effusion, pericarditis, respiratory distress syndrome, shock, skin ulcer, supraventricular tachycardia, syncope, tremor, ventricular extrasystoles and ventricular fibrillation. Cases of hypotension and gastrointestinal hemorrhage were reported in less than 0.2% of patients.

Post-marketing Experiences

In addition to adverse events reported from clinical trials, reports of angioedema and anaphylactic shock have been identified during post approval use of Synercid.

Read the Synercid (quinupristin and dalfopristin) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Iin vitro drug interaction studies have shown that Synercid significantly inhibits cytochrome P450 3A4. (See WARNINGS.)

Synercid does not significantly inhibit human cytochrome P450 1A2, 2A6, 2C9, 2C19, 2D6, or 2E1. Therefore, clinical interactions with drugs metabolized by these cytochrome P450 isoenzymes are not expected.

A drug interaction between Synercid and digoxin cannot be excluded but is unlikely to occur via CYP3A4 enzyme inhibition. Synercid has shown in vitro activity (MICs of 0.25 mcg/mL when tested on two strains) against Eubacterium lentum. Digoxin is metabolized in part by bacteria in the gut and as such, a drug interaction based on Synercid's inhibition of digoxin's gut metabolism (by Eubacterium lentum) may be possible.

Iin vitro combination testing of Synercid with aztreonam, cefotaxime, ciprofloxacin, and gentamicin, against Enterobacteriaceae and Pseudomonas aeruginosa did not show antagonism.

Iin vitro combination testing of Synercid with prototype drugs of the following classes: aminoglycosides (gentamicin),β-lactams (cefepime, ampicillin, and amoxicillin), glycopeptides (vancomycin), quinolones (ciprofloxacin), tetracyclines (doxycycline) and also chloramphenicol against enterococci and staphylococci did not show antagonism.

Read the Synercid Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 3/19/2012
This monograph has been modified to include the generic and brand name in many instances.

A A A

Synercid - User Reviews

Synercid User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Synercid sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations